Precision Oncology Solutions for Cancer Patients & Translational Drug Development
Certis Oncology Solutions was formed in 2016 with the mission to provide individualized treatment options to cancer patients. Our technology enables patients and their treatment teams to understand with certainty the most effective available therapies to treat their unique disease. Pharmaceutical companies leverage our methodology to obtain more precise, scientifically relevant data for preclinical decision-making. Findings from our science can dramatically improve lead optimization of new drug candidates, reduce development risk, and streamline the path to clinical trials.
For Drug Development
Our fully characterized tumor bank, more clinically relevant O-PDX models, and expert team of oncology researchers help you make better development decisions.
O-PDX models combined with individualized pharmacological studies determine the most efficacious treatment options for your patients, optimizing outcomes.
Certis PDX: A Patient’s Story
After My Son Was Diagnosed With Sarcoma
Certis Roundtable: This Is About Patients
Orthotopic PDX extended the patient’s life and provided a higher quality of life. Failure of the Standard of Care guided the therapy for a 2nd treatment, which was obtained by IND.
The Orthotopic PDX identified an IGF-R inhibitor as active and the patient responded well to an IGF-R inhibitor drug administered with a compassionate-use IND obtained from the FDA, based on the Orthotopic PDX results.
Eckardt M.D., Russell T.A., Murakami T., Singh A.S., Kiyuna T., Igarashi K., Kawaguchi K., Li Y., Crompton J., Dry S.M., Federman N., Chmielowski B., Shurrell E., Hoffman R.M., Eilber F.C. Clinical factors that affect the establishment of soft tissue sarcoma patient-derived orthotopic xenografts: A UCLA sarcoma program prospective clinical trial. JCO Precision Oncology, 2017.
Orthotopic PDX is a proven technique that increases the precision of cancer therapies and individualizes treatment.
There is an urgent need to personalize chemotherapy treatments.
1.68 million new cancer cases and more than 600,000 cancer deaths are projected in the USA alone this year. Half will be treated with chemotherapy. Our patented technique marks a medical breakthrough for chemo patients. We are advancing the industry from “therapy by best guess” to ”therapy by precision science.”
We transplant tumors from patients into mice where – thanks to our science – the tumors grow and metastasize the same way as in the patient. By growing multiple, simultaneous mouse implants, we can rapidly determine precise, personalized treatment for the patient.
We are working to take this life-saving technology out of the research lab and offer it to as many cancer patients as is possible.
HOW WE DO IT
We characterize and cryopreserve a portion of every tumor we receive, to enable future research and testing.
We surgically implant patient-specific tumor tissue in the orthotopically correct location in mice.
Once tumors grow, we test multiple drug therapies in multiple mice–simultaneously.
We deliver precise data about which therapies work best at fighting each unique cancer.